Skip to main content
Clinical Trials/NCT04916652
NCT04916652
Recruiting
N/A

A First-ever Research Collaboration to Characterize MRI Measured Neural Flexibility Development in Chinese Toddlers

Société des Produits Nestlé (SPN)1 site in 1 country60 target enrollmentApril 6, 2024

Overview

Phase
N/A
Intervention
Not specified
Conditions
Growth & Development
Sponsor
Société des Produits Nestlé (SPN)
Enrollment
60
Locations
1
Primary Endpoint
Neural flexibility
Status
Recruiting
Last Updated
5 months ago

Overview

Brief Summary

The overall objective is to characterize the developmental characteristics of MRI measured neural flexibility, as an index of cognitive flexibility, in Chinese toddlers (32 to 42 months old).

Detailed Description

The primary objective of this clinical study is to characterize in Chinese toddlers ages 32 - 42 months old the developmental characteristics of MRI measured neural flexibility, as an index of cognitive flexibility, and to assess a range of executive functions (inhibit, shift, emotional control, working memory, plan/organize) using the Global Executive Composite summary score obtained from the BRIEF-P standardized rating scale.

Registry
clinicaltrials.gov
Start Date
April 6, 2024
End Date
February 1, 2027
Last Updated
5 months ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Société des Produits Nestlé (SPN)
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Written informed consent has been obtained from the parent/legally acceptable representative.
  • Full-term birth (≥ 37 weeks and ≥ 2.5kg)
  • Typically developing Children aged between 32-34 months (2 years 8 months to 2 years10 month of age) at enrolment
  • Neurotypical development as assessed by interview
  • No major risk factors for learning, neurologic, or psychiatric disorder as assessed by interview \[defined as a diagnosed learning neurologic or psychiatric disorder in a first degree relative (e.g. parents, siblings)\].
  • Dietary requirement detailed below:
  • S-26 GOLD or ULTIMA GUM--fed group:
  • I. Daily consumption of S-26 GOLD or ULTIMA GUM for the last 60 days (2 months) II. Desire of the parent to continue feeding GUM during the course of the study
  • Cow's milk-fed group:
  • I. Daily consumption of cow's milk or for the last 60 days (2 months) II. Desire of the parent to continue feeding cow's milk during the course of the study

Exclusion Criteria

  • Delayed birth ( \> 41 weeks gestation) as reported in medical record
  • Birth Weight \< 2500 g or small for gestational age (birth weight below the 10th percentile) or large for gestational age (birth weight above the 90th percentile) as reported in medical record
  • History of neurological (e.g., head injury, epilepsy), psychiatric or developmental disorder in the toddler as assessed by interview
  • History of diagnosed neurological (e.g., head injury, epilepsy), psychiatric or developmental disorder in parents or siblings, as assessed by interview
  • In utero exposure to alcohol abuse or illicit substances as defined as diagnosis of current substance use disorder in the biological mother and guidelines set by the American College of Obstetricians and Gynecologists and the Royal College of Physicians
  • Multiple birth as reported in medical record
  • Complicated pregnancy (e.g., preeclampsia, gestational diabetes) as assessed by medical interview/ medical record
  • Abnormal screening laboratory values and studies considered to be clinically significant in the opinion of the Investigator (e.g., metabolic disease screening, neonatal bilirubin)

Outcomes

Primary Outcomes

Neural flexibility

Time Frame: at baseline and 42 months after baseline

MRI-derived neural flexibility associated with cognitive flexibility (including anterior cingulate cortex, dorsolateral prefrontal cortex, ventrolateral prefrontal cortex, anterior insula, interior frontal junction, superior parietal lobule, precuneus, intraparietal sulcus, and temporoparietal junction)

Global Executive Composite (GEC) score

Time Frame: at baseline and 42 months of age

executive functions (inhibit, shift, emotional control, working memory, plan/organize) using the Global Executive Composite summary score obtained from the BRIEF-P standardized rating scale

Secondary Outcomes

  • Brain structure (brain regions volume)(at baseline and 42 months of age)
  • Brain structure (cortical surface area)(at baseline and 42 months of age)
  • Brain structure (cortical thickness)(at baseline and 42 months of age)
  • Brain structure (myelination)(at baseline and 42 months of age)
  • Brain function (network topologies)(at baseline and 42 months of age)
  • Brain function (connection strengths)(at baseline and 42 months of age)
  • Cognitive flexibility(at baseline and 42 months of age)
  • Children development(at baseline and 42 months of age)
  • School readiness(at 42 months of age)
  • Children behavior (for toddlers)(at baseline and 42 months of age)
  • Curiosity(at baseline and 42 months of age)
  • Sleep quality(at baseline and 42 months of age)
  • Home environment(at baseline and 8 months after baseline)
  • Feeding practice(at baseline and 42 months of age)
  • Fecal microbiota composition(at baseline and 42 months of age)

Study Sites (1)

Loading locations...

Similar Trials